Clinical Study Protocol M12-817:A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women
Heavy periods due to Uterine fibroids
Sponsor: AbbVie
Enrolling: Female Patients Only
IRB Number: AAAQ6714
U.S. Govt. ID: NCT02691494
Contact: Reena M. Vattakalam: / rmv2110@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the safety of study drug elagolix and how elagolix works when compared to placebo (pill containing no active medication) in reducing heavy menstrual bleeding, the major symptom of uterine fibroids.
This study is closed
Investigator
Jin Hee Kim, MD
Do You Qualify?
Do you experience monthly periods? Yes No
Do you have heavy periods associated with uterine fibroids? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Reena M. Vattakalam
rmv2110@cumc.columbia.edu

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE